Android app on Google Play

AcelRx Pharma (ACRX) Gets U.S. Patent for 'Small-Volume Oral Transmucosal Dosage Forms'

June 20, 2012 7:32 AM EDT Send to a Friend
Get Alerts ACRX Hot Sheet
Trade ACRX Now!
Join SI Premium – FREE
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Patent and Trademark Office (USPTO) issued AcelRx Patent Number 8,202,535 entitled "Small-Volume Oral Transmucosal Dosage Forms." The patent describes a method of treating pain by administering a small-volume solid tablet containing sufentanil by adhering to the oral mucosa. This newly issued patent will provide intellectual property protection for sufentanil NanoTab based products through late 2030.

This method patent is the first patent the USPTO has issued in relation to sublingual sufentanil NanoTabs. AcelRx exclusively owns this patent, which provides domestic protection for each of AcelRx's four development programs. The 8,202,535 patent covers AcelRx's proprietary NanoTab technology for delivering sufentanil with claims to elements of a method for treating pain by administering a small volume (<15mcl) substantially homogenous solid tablet containing the active ingredient sufentanil to the oral mucosa of a subject while generating a minimal saliva response and delivering the majority of the drug through the transmucosal route resulting in consistent pharmacokinetics.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment